RESUMEN
Parkinson's disease (PD) is a progressive neurodegenerative disease with a high clinical heterogeneity. According to its motor symptoms, PD patients are divided into predominant tremor-dominant, postural instability and gait difficulty-dominant/akinetic-rigid and mixed subtypes. Different subtypes show different prognostic characteristics and different sensitivities to drugs. Therefore, the early classification of PD is of great significance for the treatment and prognosis of the disease. This paper reviews the clinical classification methods of different subtypes of PD, summarizes the latest biochemical markers and imaging features, and analyzed the differences in incidence, prognosis and pathological mechanism. The current clinical treatment drugs and methods have been preliminarily targeted for treatment based on PD classification, and there are many animal models of PD subtypes have been studied, providing new methods and strategies for mechanism research and preclinical pharmacodynamics evaluation of PD subtypes.
RESUMEN
Aim Ischemic brain injury ( IBI) is one of the main causes of death and disability worldwide.Faced with this serious disease, human beings still laek effective treatment methods.With the advancement of science and the improvement of medi¬cal standards, the basic and clinieal research of cerebrovaseular diseases continues to develop to a higher and more in-depth lev¬el.Due to the limitations of clinical researeh, animal models of eerebral ischemia have beeome an indispensable tool for studying the mechanism of cerebrovascular disease damage and prevention and treatment measures.It is necessary to construct scientific, standard and standardized experimental methods and proee- dures..Methods This artiele combines our laboratory s long-tenn praetieal experienee in preparing animal models of cerebral is¬chemia.comprehensive literature data, comparison and evalua¬tion of the characteristics of commonly used animal models.Re¬sults Standardized preparation methods and discusses the com¬mon criteria for preparing experimental animal models of cerebral Ischemia, which is the occurrence of cerebral ischemia injury.Conclusions 'Hie researeh of mechanism and the researeh and de¬velopment of prevention and treatment drugs provide reliable ex¬perimental animal models.
RESUMEN
Cystine/glutamate antiporter [system Xc(-)] is a sodium independent amino acid transporter, which is a heterodimer composed of light chain subunit xCT and heavy chain subunit 4F2hc (CD98) through covalent disulfide bond. System Xc(-) typically mediates cystine uptake and glutamate output, helps to maintain the balance of glutamate, cystine and cysteine inside and outside the cell, regulates the level of glutamate inside and outside the membrane and the synthesis of intracellular glutathione, thus affecting oxidative stress and glutamate neurotoxicity. This review expounds the structure and function of system Xc(-), analyzes the role of the transporter in physiology and pathology, discusses the role and mechanism in different diseases, and discusses the specific research progress of system Xc(-) as a drug target. This review summarizes the research status of system Xc(-) and provides theoretical guidance for further research on system Xc(-) and drug discovery.